Blood tests can detect Alzheimer’s disease pathology in people who have no symptoms yet, and research suggests they may eventually replace more invasive diagnostic methods. However, no blood test has received FDA approval as a standalone diagnostic tool for Alzheimer’s disease. Several candidates are in clinical trials, and early results show they can identify amyloid and tau proteins—the hallmarks of Alzheimer’s pathology—with impressive accuracy, but regulatory approval requires larger, more rigorous studies proving they work reliably across diverse populations and clinical settings.
The promise of a simple blood test lies in accessibility. A 70-year-old concerned about memory changes could potentially get results from a routine lab draw instead of undergoing a positron emission tomography scan (which costs thousands of dollars and involves radioactive tracers) or a lumbar puncture (which many patients find uncomfortable and risky). Yet between promising research and approved clinical tools stands a significant gap: the tests work in controlled research environments, but regulators need evidence they’ll work when ordered by a primary care doctor in a busy clinic.
Table of Contents
- What Can Current Blood Tests for Alzheimer’s Detect?
- Why These Tests Lack Clinical Approval Despite Promising Results
- The Clinical Trial Landscape and Current Evidence
- Blood Tests Versus Existing Diagnostic Methods
- Key Limitations and What Could Go Wrong
- The Role of Blood Tests in Research and Risk Prediction
- When Approval Might Come and What It Would Mean
What Can Current Blood Tests for Alzheimer’s Detect?
Blood tests for Alzheimer’s measure proteins associated with the disease—primarily amyloid-beta, phosphorylated tau (tau-181, tau-217, and tau-181), and neurofilament light chain. These proteins accumulate in the brain years before memory loss appears, a phenomenon researchers call preclinical Alzheimer’s disease. A blood test can identify this accumulation, potentially catching the disease decades before symptoms would make a diagnosis obvious. The most studied biomarkers focus on the amyloid hypothesis, which posits that accumulation of amyloid-beta protein triggers a cascade leading to Alzheimer’s.
Research published in recent years has shown that plasma phosphorylated tau-181 can distinguish people with Alzheimer’s pathology from those with normal brains with roughly 90% accuracy in research cohorts. This is substantial. For context, a person presenting to a memory clinic with cognitive complaints might undergo a spinal tap (cerebrospinal fluid analysis) or a PET scan to confirm Alzheimer’s; a blood test showing similar accuracy would be revolutionary for convenience. Yet these numbers come from carefully selected research participants—often younger, educated, and cognitively normal. What happens when a 85-year-old with diabetes, heart disease, and multiple medications gets the test? What about racial and ethnic groups underrepresented in Alzheimer’s research? Those are open questions.
Why These Tests Lack Clinical Approval Despite Promising Results
The FDA distinguishes between research-grade biomarkers (useful for science) and clinical-grade diagnostics (useful for guiding patient care). A blood test might be 90% accurate in a research setting but still not approved because regulators need evidence that doctors can use it to make decisions that improve patient outcomes. This is the central barrier. Approving a blood test as a diagnostic tool requires demonstrating that the test results correlate with disease progression in real-world patients, that test results guide effective treatment, and that using the test changes outcomes for the better. For Alzheimer’s, this is complicated because no disease-modifying treatment definitively prevents or reverses cognitive decline once it’s advanced.
Lecanemab, a monoclonal antibody targeting amyloid-beta, has shown modest slowing of cognitive decline in early symptomatic Alzheimer’s disease—but it requires intravenous infusion every two weeks and carries a small risk of amyloid-related imaging abnormalities (brain microhemorrhages or microinfarcts visible on MRI). These risks and burdens mean that a positive blood test isn’t automatically actionable advice. Another barrier: standardization. Different laboratories might process blood samples differently, use different assays, or report results in different units. Before a test can be approved for clinical use, the industry must establish standardized procedures. This work is ongoing but takes years.
The Clinical Trial Landscape and Current Evidence
Several blood-based biomarkers are in late-stage clinical trials. The most prominent is phosphorylated tau-181, which has been studied in thousands of cognitively normal and mildly impaired individuals. These trials compare blood test results to established diagnostic methods (amyloid PET, tau PET, and cerebrospinal fluid biomarkers) and follow participants over years to see who develops cognitive decline. A realistic example: imagine a 60-year-old with a family history of Alzheimer’s who worries about her memory. She gets a blood test in a research study and learns her amyloid-beta is elevated—a risk factor.
She then receives annual cognitive testing and repeat blood tests for several years. Researchers track whether her cognition declines faster than people with normal amyloid levels. If the pattern holds across thousands of participants, this data supports regulatory approval. But that study takes years, involves thousands of participants, and costs tens of millions of dollars. As of early 2025, no major blood test for Alzheimer’s has completed the FDA approval process for clinical diagnostic use. Several companies are pursuing approval pathways, particularly for tests measuring phosphorylated tau and amyloid-beta ratios, but the timelines are uncertain.
Blood Tests Versus Existing Diagnostic Methods
Currently, Alzheimer’s diagnosis relies on clinical assessment (history, neuropsychological testing) combined with biomarker confirmation via PET imaging or cerebrospinal fluid analysis. A PET scan costs $3,000 to $5,000, requires travel to specialized imaging centers, and involves low-dose radiation. A cerebrospinal fluid test requires a lumbar puncture—a procedure that, while generally safe in experienced hands, carries small risks of infection, meningitis, and post-procedure headache. Many patients prefer not to undergo it. A blood test would be cheaper (potentially $200 to $500 if approved and covered by insurance), faster (results in days rather than weeks), and accessible at any lab that can draw blood.
However, a blood test would not replace imaging entirely. Imaging shows the physical structure of the brain and can rule out stroke, tumor, or other conditions mimicking Alzheimer’s. A blood test identifies proteins but doesn’t visualize the brain. A complete diagnostic workup would likely still include some imaging. The practical tradeoff: blood tests promise efficiency for people with suspected early cognitive decline but can’t replace the structural information imaging provides. They’re best imagined as a screening or triage tool—a way to narrow who needs further evaluation.
Key Limitations and What Could Go Wrong
False positives are a major concern. Amyloid pathology in the brain is necessary for Alzheimer’s diagnosis but not sufficient; some cognitively normal older adults have amyloid accumulation but never develop dementia. If a blood test becomes widely available, many people will test positive for amyloid and never know whether they’ll develop cognitive symptoms. This raises the specter of “worried well”—people without cognitive complaints undergoing expensive follow-up testing and potentially unnecessary treatment because a blood test identified asymptomatic pathology. Another limitation: blood biomarkers reflect systemic pathology but vary with genetics, age, ApoE status, and other factors. Two people with identical phosphorylated tau-181 levels might have very different cognitive trajectories.
The test is probabilistic, not deterministic. For a patient making decisions about their health, this uncertainty is uncomfortable. Will insurance cover treatment based on a positive blood test alone? Will patients be motivated to make lifestyle changes (exercise, Mediterranean diet, cognitive engagement) based on an asymptomatic blood test result? These practical questions remain unanswered. A third limitation: most validation studies have enrolled predominantly White, educated, affluent participants. Whether phosphorylated tau-181 performs equally well in African American, Hispanic, or Asian populations is unclear. Approval should require demonstration of equity across diverse groups, but this adds years to development.
The Role of Blood Tests in Research and Risk Prediction
Outside the clinic, blood biomarkers are transforming Alzheimer’s research. Large prevention trials—studies testing whether drugs or lifestyle interventions prevent cognitive decline in cognitively normal people with Alzheimer’s pathology—now rely on blood tests for enrollment and participant stratification. This has democratized access to prevention research.
Instead of requiring expensive, time-consuming PET scans to enroll in a trial, researchers can screen thousands of people with blood tests and identify those with elevated pathology. For example, if a pharmaceutical company develops a new drug believed to slow amyloid accumulation, they might use blood tests to identify cognitively normal 55-year-olds with high amyloid and recruit them into a prevention trial. Blood tests make such trials feasible and affordable.
When Approval Might Come and What It Would Mean
Industry and regulatory timelines suggest clinical approval for at least one blood test biomarker is plausible within the next two to three years, though this is speculative. Regulatory agencies worldwide are working with manufacturers to clarify the pathway. The key milestones are completion of large validation studies, standardization of assays, and demonstration that blood test results can guide clinical decisions that improve outcomes.
When approval comes, blood tests will likely be positioned initially as tools for cognitive specialists and memory clinics—settings where patients already have cognitive concerns and expert interpretation is available. Broader use in primary care will probably follow only after years of real-world experience demonstrating safety, utility, and cost-effectiveness. A positive blood test alone won’t replace the cognitive evaluation, imaging, and clinical judgment that diagnosis requires; it will supplement them, potentially making the diagnostic process faster and more accessible for people with genuine cognitive symptoms.
- —
